Suppr超能文献

接受放射治疗的硬纤维瘤患者的长期疗效:10 年随访结果更新和对年轻患者放射治疗作用的再评估。

Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients.

机构信息

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1167-1174. doi: 10.1016/j.ijrobp.2018.12.012. Epub 2018 Dec 12.

Abstract

PURPOSE

To update our experience with long-term outcomes in patients with desmoid fibromatosis treated with radiation therapy (RT) and to characterize factors associated with increased risk of local recurrence.

METHODS AND MATERIALS

We reviewed the records of 209 consecutive patients with desmoid fibromatosis treated with RT, either alone or as combined-modality therapy (CMT) with surgery, at our institution from 1965 to 2015.

RESULTS

Median follow-up time was 98 months (range, 1-509 months). The 5- and 10-year local control (LC) was 71% and 69%, respectively. Fifty-nine patients (28%) experienced a local recurrence at a median time of 23 months (interquartile range, 15-38 months). Among all patients, on multivariable analysis, adjusting for anatomic site, size, age, treatment era (>2005 vs ≤2005), treatment approach (RT alone vs CMT), and an interaction between age and treatment, we found only age ≤30 years (hazard ratio [HR], 2.94; P = .005; 95% confidence interval [CI], 1.38-6.27) and large tumor size >10 cm (HR, 2.51; P = .03; 95% CI, 1.09-5.78) to be correlated with poorer LC. Notably, for patients receiving RT alone, the 5-year LC was 43% for patients ≤30 years old versus 75% for >30 years old (P < .001). On multivariable analyses, for patients receiving RT alone, the only factor associated with inferior LC was age ≤30 years (HR, 2.87; P = .001; 95% CI, 1.51-5.47). The same was true for patients treated with CMT; age ≤30 years was the only factor associated with inferior LC (HR, 5.36; P = .01; 95% CI, 1.40-20.58).

CONCLUSIONS

Among all patients with desmoid fibromatosis, RT is an effective local therapy for tumor control. However, young patients ≤ 30 years have notably high rates of local recurrence regardless of treatment strategy, which requires further study. Treatment decisions should be risk-adapted by large referral centers with multidisciplinary expertise in desmoid management.

摘要

目的

更新我们在接受放射治疗(RT)的局限性纤维瘤病患者中获得的长期结果经验,并描述与局部复发风险增加相关的因素。

方法和材料

我们回顾了 1965 年至 2015 年期间在我们机构接受 RT 治疗(单独治疗或与手术联合进行的综合治疗(CMT))的 209 例局限性纤维瘤病患者的病历。

结果

中位随访时间为 98 个月(范围,1-509 个月)。5 年和 10 年局部控制率(LC)分别为 71%和 69%。59 例患者(28%)在中位时间 23 个月(四分位距,15-38 个月)时发生局部复发。在所有患者中,通过多变量分析,在调整解剖部位、大小、年龄、治疗时代(>2005 年与≤2005 年)、治疗方法(单独 RT 与 CMT)以及年龄与治疗之间的相互作用后,我们仅发现年龄≤30 岁(风险比[HR],2.94;P=0.005;95%置信区间[CI],1.38-6.27)和肿瘤较大(>10cm)(HR,2.51;P=0.03;95%CI,1.09-5.78)与较差的 LC 相关。值得注意的是,对于接受 RT 单独治疗的患者,≤30 岁的患者 5 年 LC 为 43%,而>30 岁的患者为 75%(P<0.001)。在多变量分析中,对于接受 RT 单独治疗的患者,唯一与 LC 较差相关的因素是年龄≤30 岁(HR,2.87;P=0.001;95%CI,1.51-5.47)。对于接受 CMT 治疗的患者也是如此;年龄≤30 岁是唯一与较差 LC 相关的因素(HR,5.36;P=0.01;95%CI,1.40-20.58)。

结论

在所有局限性纤维瘤病患者中,RT 是一种有效的局部肿瘤控制治疗方法。然而,≤30 岁的年轻患者局部复发率明显较高,无论治疗策略如何,这都需要进一步研究。具有多学科纤维瘤病管理专业知识的大型转诊中心应根据风险适应性做出治疗决策。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验